drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody immunotherapy (anti-CD20)
drug_description
Glycoengineered chimeric IgG1 anti-CD20 monoclonal antibody (Briumvi) that selectively depletes CD20+ pre-B and mature B lymphocytes via enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), reducing B-cell antigen presentation, proinflammatory cytokine secretion, and pathogenic antibody production to dampen CNS neuroinflammation in multiple sclerosis.
nci_thesaurus_concept_id
C91078
nci_thesaurus_preferred_term
Ublituximab
nci_thesaurus_definition
A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ublituximab specifically binds to the B cell-specific cell surface antigen CD20, thereby potentially inducing a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies. Ublituximab has a specific glycosylation profile, with a low fucose content, that may enhance its ADCC response against malignant B cells.
drug_mesh_term
ublituximab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Glycoengineered anti‑CD20 IgG1 monoclonal antibody that binds CD20 on pre‑B and mature B cells and depletes them via enhanced antibody‑dependent cellular cytotoxicity (ADCC) and complement‑dependent cytotoxicity (CDC), thereby reducing B‑cell antigen presentation, proinflammatory cytokine release, and pathogenic antibody production to dampen CNS neuroinflammation in multiple sclerosis.
drug_name
Ublituximab
nct_id_drug_ref
NCT06629428